Genmab A/S announced a share‑buyback program that will allow the company to repurchase up to 342,130 shares, with a maximum aggregate value of 725 million DKK. The first repurchase is scheduled for February 18, 2026, and the program is expected to conclude by March 31, 2026. The buyback is executed through a non‑discretionary instruction with Danske Bank, which will make independent trading decisions on the company’s behalf.
The buyback announcement coincided with the release of Genmab’s Q4 2025 earnings. Total revenue rose 8.74% to $1.12 billion, beating the consensus estimate of $1.03 billion. The company’s earnings per share were $0.385, a miss of $0.045 or 10.57% below the $0.4305 estimate. The revenue beat was driven by strong demand for the company’s proprietary medicines, particularly Epkinly and Tivdak, while the EPS miss reflected higher operating costs and a one‑time charge related to restructuring activities.
Management highlighted the company’s robust financial position, noting that cash exceeds debt and the current ratio stands at 6.03. In the earnings call, the CEO emphasized that Genmab entered 2026 with a diversified revenue base and a late‑stage pipeline positioned to drive growth into the 2030s. The company guided for 2026 revenue of $4.1 billion to $4.4 billion, up from the prior guidance of $4.1 billion to $4.4 billion, and operating profit of $0.90 billion to $1.40 billion, reflecting confidence in maintaining profitability while investing in strategic initiatives.
The share‑buyback program is intended to honor commitments under Genmab’s Restricted Stock Unit (RSU) program and to provide EPS‑accretive capital allocation. By repurchasing shares, the company reduces the share count, which can support earnings per share and signal confidence in its long‑term value creation. The program also helps mitigate dilution from warrant exercises and aligns shareholder interests with management’s performance objectives.
Guidance for 2026 indicates that Genmab expects continued momentum in its core product portfolio, with particular emphasis on Epkinly’s FDA approval for second‑line follicular lymphoma. The company’s operating margin is projected to remain strong, supported by high gross profit margins of 94.36% and disciplined cost management. Management’s outlook suggests a focus on sustaining growth while preserving cash to fund future pipeline development and strategic investments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.